LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
3.25
3.25
Faixa anual
1.81
5.06
Mudança diária
-1.81%
Mudança mensal
+1.25%
Mudança em 6 meses
+58.54%
Mudança anual
+16.49%
Fechamento anterior
3.3 1
Open
3.2 5
Mínimo
3.2 5
High
3.2 5
Volume
4
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor 20202021202220232024 TTM

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Notícias